PT  - JOURNAL ARTICLE
AU  - Althouse, Benjamin M.
AU  - Baker, Charlotte
AU  - Smits, Peter D
AU  - Gratzl, Samuel
AU  - Lee, Ryan H
AU  - Cartwright, Brianna M Goodwin
AU  - Simonov, Michael
AU  - Wang, Michael D
AU  - Stucky, Nicholas L
TI  - COVID treatment and in-hospital length of stay inequalities between race in the US over time
AID  - 10.1101/2022.09.30.22280586
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.09.30.22280586
4099  - http://medrxiv.org/content/early/2022/10/01/2022.09.30.22280586.short
4100  - http://medrxiv.org/content/early/2022/10/01/2022.09.30.22280586.full
AB  - Introduction Demonstrated health inequalities persist in the United States. SARS-CoV-2 (COVID) has been no exception, with access to treatment and hospitalization differing across race or ethnic group. Here we aim to assess differences in treatment with remdesivir and hospital length of stay across four waves of the pandemic.Methods Using a subset of the Truveta data we examine odds ratios (OR) of in-hospital remdesivir treatment and risk ratios (RR) of in-hospital length of stay between Black or African American (Black) to white patients. We adjusted for confounding factors such as age, sex, and comorbidity status.Results There were statically significant lower rates of remdesivir treatment and longer in-hospital lengths of stay comparing Black patients to white patients early in the pandemic (OR for treatment: 0.88, 95% confidence interval [CI]: 0.80, 0.96; RR for length of stay: 1.17, CI: 1.06, 1.21). Rates became close to parity between groups as the pandemic progressed.Conclusions While inpatient remdesivir treatment rates increased and length of stay decreased over the beginning course of the pandemic, there are still inequalities in patient care.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board of Providence Health Care waived ethical approval for this work (STUDY2022000435).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesCode necessary to generate all analyses and figures is included in a GitHub repository at https://github.com/Truveta/althouse_et_al_covid_equity